Your browser doesn't support javascript.
loading
Chinese herbal medicine for the treatment of chronic fatigue syndrome: A systematic review and meta-analysis.
Zhang, Yang; Jin, Fangfang; Wei, Xing; Jin, Qiuyu; Xie, Jingri; Pan, Yujia; Shen, Wenjuan.
Afiliação
  • Zhang Y; Department of Internal Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
  • Jin F; Department of Internal Medicine, Heilongjiang University of Chinese Medicine, Harbin, China.
  • Wei X; Department of Internal Medicine, Heilongjiang University of Chinese Medicine, Harbin, China.
  • Jin Q; Department of Internal Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
  • Xie J; Department of Internal Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
  • Pan Y; Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, China.
  • Shen W; Department of Obstetrics and Gynecology, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Front Pharmacol ; 13: 958005, 2022.
Article em En | MEDLINE | ID: mdl-36249791
ABSTRACT

Objectives:

This meta-analysis aimed to assess the effectiveness and safety of Chinese herbal medicine (CHM) in treating chronic fatigue syndrome (CFS).

Methods:

Nine electronic databases were searched from inception to May 2022. Two reviewers screened studies, extracted the data, and assessed the risk of bias independently. The meta-analysis was performed using the Stata 12.0 software.

Results:

Eighty-four RCTs that explored the efficacy of 69 kinds of Chinese herbal formulas with various dosage forms (decoction, granule, oral liquid, pill, ointment, capsule, and herbal porridge), involving 6,944 participants were identified. This meta-analysis showed that the application of CHM for CFS can decrease Fatigue Scale scores (WMD -1.77; 95%CI -1.96 to -1.57; p < 0.001), Fatigue Assessment Instrument scores (WMD -15.75; 95%CI -26.89 to -4.61; p < 0.01), Self-Rating Scale of mental state scores (WMD -9.72; 95%CI-12.26 to -7.18; p < 0.001), Self-Rating Anxiety Scale scores (WMD -7.07; 95%CI -9.96 to -4.19; p < 0.001), Self-Rating Depression Scale scores (WMD -5.45; 95%CI -6.82 to -4.08; p < 0.001), and clinical symptom scores (WMD -5.37; 95%CI -6.13 to -4.60; p < 0.001) and improve IGA (WMD 0.30; 95%CI 0.20-0.41; p < 0.001), IGG (WMD 1.74; 95%CI 0.87-2.62; p < 0.001), IGM (WMD 0.21; 95%CI 0.14-0.29; p < 0.001), and the effective rate (RR = 1.41; 95%CI 1.33-1.49; p < 0.001). However, natural killer cell levels did not change significantly. The included studies did not report any serious adverse events. In addition, the methodology quality of the included RCTs was generally not high.

Conclusion:

Our study showed that CHM seems to be effective and safe in the treatment of CFS. However, given the poor quality of reports from these studies, the results should be interpreted cautiously. More international multi-centered, double-blinded, well-designed, randomized controlled trials are needed in future research. Systematic Review Registration [https//www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022319680], identifier [CRD42022319680].
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article